tirzepatide phase 3 mash in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review Eli Lilly's tirzepatide shows promise

Future clinical trials should include larger sample sizes and longitudinal monitoring in individuals with obesity who do not have diabetes

High-Protein Whole Foods These foods are commonly well-tolerated with GLP-1 medications and make it easier to get protein without large portions

It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes." What Happens Next The introductory offer runs from November 17 through March 31.

Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when: The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable) Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable An SGLT-2 inhibitor is contraindicated or not tolerated NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised often alongside or instead of metformin due to its organ-protective benefits

Some people notice improvements in pain, bloating, or sleep within a few weeks, while other benefitssuch as reduced inflammation or hormonal improvementsmay take several months of consistent use

Forced swimming test Behavioural despair test in which the degree to which a rodent swims when placed in a cylinder filled with water from which it cannot escape is taken as a measure of antidepressant activity